RBT-101 / Radiant Biotherap - LARVOL DELTA

Multabodies: A next-generation approach for cancer immunotherapy and 4-1BB agonist therapy (AACR 2025) - "However clinical development has been hindered by severe liver toxicity (i.e., urelumab), or insufficient single agent activity, as seen with utomilumab. Furthermore, RBT101 also provided long-term protection in a tumor rechallenge study, suggesting generation of a durable immunological memory response driven by RBT101. These data suggest the Multabody™ platform provides a novel approach to delivering a 4-1BB therapeutic with a differentiated profile to address an unmet clinical need in cancer immunotherapy for patients with solid malignancies."

Oncology • Solid Tumor • TNFRSF9

Radiant Biotherapeutics to Present New Data from Lead Oncology Program at SITC 2025 Annual Meeting (Businesswire) - "RBT-101, Radiant’s lead oncology program and 4-1BB agonist, demonstrated robust, durable and complete tumor regression without liver toxicity in MC38 colorectal mouse tumor model....RBT-101 demonstrated long-lived anti-tumor immunological memory; no detectable tumor growth was observed in mice that were re-challenged with MC38 tumor cells after previous successful treatment."

Preclinical • Colorectal Cancer

Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody Platform (Businesswire) - "Radiant Biotherapeutics...announced it has closed a $35 million Series A financing. The round is co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures of Canada....The funds will enable Radiant to further develop the company’s lead clinical candidate, 4-1BB, and move it towards clinical trials."

Financing • Oncology • Solid Tumor